Attached files

file filename
EX-99.3 - EXHIBIT 99.3 - AMAG PHARMACEUTICALS, INC.ex993ferahemedata.htm
EX-99.2 - EXHIBIT 99.2 - AMAG PHARMACEUTICALS, INC.a1q2017earningsdeckfinal.htm
EX-99.1 - EXHIBIT 99.1 - AMAG PHARMACEUTICALS, INC.ex991q12017earningsrelease.htm




UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): May 2, 2017

AMAG PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation)
001-10865
 
04-2742593
(Commission File
Number)
 
(IRS Employer Identification
No.)
1100 Winter St.
 
 
Waltham, Massachusetts
 
02451
(Address of principal executive
offices)
 
(Zip Code)

(617) 498-3300
(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐









Item 2.02. Results of Operations and Financial Condition.
 
The following information and Exhibit 99.1 and Exhibit 99.2 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, (the “Securities Act”) except as expressly set forth by specific reference in such filing.
 
On May 2, 2017, AMAG Pharmaceuticals,Inc. (“AMAG” ) issued a press release entitled “AMAG Pharmaceuticals Announces First Quarter 2017 Financial Results” regarding its operating results for the quarter ended March 31, 2017 and its intention to hold a conference call to discuss AMAG’s financial and operating results and recent developments. A copy of AMAG’s press release is furnished herewith as Exhibit 99.1 and a copy of the presentation slides to be used during the conference call is furnished herewith as Exhibit 99.2.

Item 7.01. Regulation FD Disclosure.

The following information and Exhibit 99.3 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act, except as expressly set forth by specific reference in such filing.

On May 2, 2017, AMAG issued a press release entitled "AMAG Announces Positive Topline Data From Phase 3 Feraheme (ferumoxytol) Label Expansion Study" regarding a clinical trial evaluating Feraheme. A copy of the press release is furnished herewith as Exhibit 99.3.

Item 9.01. Financial Statements and Exhibits.
 
(d) Exhibits.
 
AMAG hereby furnishes the following exhibits:
 
Exhibit
Number
 
Description
99.1
 
Press release entitled “AMAG Pharmaceuticals Announces First Quarter 2017 Financial Results” issued by AMAG Pharmaceuticals, Inc. on May 2, 2017.
99.2
 
Copy of AMAG Pharmaceuticals, Inc.’s presentation slides dated May 2, 2017.
99.3
 
Press release entitled “AMAG Announces Positive Topline Data From Phase 3 Feraheme (ferumoxytol) Label Expansion Study” issued by AMAG Pharmaceuticals, Inc. on May 2, 2017.








SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
AMAG PHARMACEUTICALS, INC.
 
By:
/s/ Joseph D. Vittiglio
 
 
Joseph D. Vittiglio
General Counsel, Senior Vice President of Legal Affairs, Technical Operations and Quality and Secretary
 
 
 
Date: May 2, 2017







EXHIBIT INDEX

Exhibit
Number
Description
99.1
 
Press release entitled “AMAG Pharmaceuticals Announces First Quarter 2017 Financial Results” issued by AMAG Pharmaceuticals, Inc. on May 2, 2017.
99.2
 
Copy of AMAG Pharmaceuticals, Inc.’s presentation slides dated May 2, 2017.
99.3
 
Press release entitled “AMAG Announces Positive Topline Data From Phase 3 Feraheme (ferumoxytol) Label Expansion Study” issued by AMAG Pharmaceuticals, Inc. on May 2, 2017.